REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced that four abstracts related to clinical study findings of OCR-002 (ornithine phenylacetate) in development for the treatment and prevention of hepatic encephalopathy (HE) have been selected for presentation at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held October 20-24, 2017, in Washington, D.C.
"OCR-002 (Ornithine Phenylacetate) is a Potent Ammonia Scavenger as Demonstrated in Phase 2b STOP-HE Study" - Publication Number: 219
"STOP-HE: A Randomized, Double-blind, Placebo-controlled Study of OCR-002 in Patients with Hepatic Encephalopathy" - Publication Number: 502
"Geographic Differences for Patients Enrolled in STOP-HE: A Randomized, Phase 2 Study of OCR-002 for Hepatic Encephalopathy" - Publication Number: 499
"An Open-Label Crossover Study of the Pharmacokinetics of Ornithine Phenylacetate (OCR-002) after IV and Oral Doses in Subjects with Cirrhosis" - Publication Number: 501
"The Liver Meeting 2017 is a preeminent forum for the field of hepatology and we are very pleased to have been granted four opportunities to present important clinical data from our development programs to more than 10,000 hepatology health professionals expected to attend," said Stan Bukofzer, M.D., Chief Medical Officer of Ocera.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (i.v.) and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.
Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with FDA later this year to review the i.v. program and discuss potential development paths forward.
Ocera is currently evaluating its oral tablet form of OCR-002 in a Phase 2a study in patients with cirrhosis as a chronic use option to maintain remission of HE. Results of this study are expected to be published by the end of 2017. For additional information, please see www.ocerainc.com.
Ocera Therapeutics, Inc.